Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Opthea Limited (OPT)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases. They are developing their Phase 3-ready product candidate, OPT-302, a biologic designed to inhibit VEGF-C and VEGF-D, to complement VEGF-A inhibitors for the treatment of ophthalmic diseases. Anti-VEGF-A therapies represent the standard of care for wet age-related macular degeneration, or AMD, and other retinal diseases; however, there remains a significant unmet medical need as many patients do not adequately respond to these treatments. Their lead indication for OPT-302 combination therapy is wet AMD, a chronic, progressive disease and the leading cause of vision loss for individuals over the age of 50. In a 366-patient Phase 2b clinical trial for the treatment of wet AMD, 2.0 mg OPT-302, in combination with a standard of care anti-VEGF-A therapy, ranibizumab (Lucentis), met the primary endpoint of a statistically significant superior mean gain in visual acuity over ranibizumab monotherapy at week 24. They intend to initiate two pivotal Phase 3 clinical trials in treatment-naive patients with wet AMD to evaluate the efficacy and safety of OPT-302 in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy in the first half of 2021. They expect to report topline data from these Phase 3 clinical trials in 2023.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Megan Baldwin Michael Tonroe
Employees Founded
8 1984

Contacts

Address: Level 4 650 Chapel Street South Yarra, Victoria 3141 Australia

Telephone: + 61 3 9826 0399

Web page: http://www.opthea.com

IPO information

First Trade Date 10/16/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 9.3
Shares Revised (MM) 9.5
Expected offer amount (MM) $150
Realized offer amount(MM) $128.25

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) $0.09
Net Income (Loss) (MM) $-16.5

Voting

What do you think will happen with the OPT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Citigroup

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Citigroup/ SVB Leerink
CO-Managers
Truist Securities/ Oppenheimer & Co

Sector: Healthcare

Tweets about $OPT

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats